European Launch of ResistancePlus MG FleXible for the GeneXpert System
SpeeDx Pty, Ltd. today announced the European launch of Resistance Plus® MG FleXible, the first sample-to-answer test for detecting the sexually transmitted infection (STI) Mycoplasma genitalium (Mgen) and markers associated with azithromycin resistance. Cepheid is the exclusive distribution partner of this test, available through Cepheid’s FleXible Cartridge programme for the GeneXpert System.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191215005039/en/
ResistancePlus MG FleXible is now selling in France and the U.K. (to be followed by rest of EU, Australia and New Zealand). This successful collaboration between SpeeDx and Cepheid is the first sample-to-answer test for Mgen and macrolide resistance - exclusively distributed by Cepheid. (Photo: Business Wire)
Management guidelines around the world, including those recently updated in France1 and the U.K.2, reference testing the macrolide resistance status of Mgen infections in order to more effectively treat patients. Mgen can cause symptoms such as urethritis, cervicitis, endometritis and pelvic inflammatory disease, and has been linked to reproductive health complications including pre-term birth and infertility.2,3 Due to the challenges of rising antimicrobial resistance and a lack of clear data that asymptomatic infection leads to protracted health complications, Mgen testing guidelines are unanimous in their recommendation to only test symptomatic individuals.
“This is an important test expansion for the thousands of GeneXpert Systems on the market,” said Colin Denver, SpeeDx CEO. “ Resistance Plus MG FleXible enables Resistance Guided Therapy, supporting more clinicians to adhere to testing guidelines and maximising effective care for their patients infected with Mgen.”
Both SpeeDx and Cepheid will be showcasing Resistance Plus MG at RICAI (Réunion Interdisciplinaire de Chimiothérapie Anti-Infectieuse) December 15th and 16th in Paris. Visit SpeeDx booth #41bis and Cepheid booth #18 to learn more.
SpeeDx has developed a molecular diagnostics test portfolio, principally for infectious diseases, that provides both identification as well as therapeutic guidance capabilities. The company is based in Australia with offices in Austin and London, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. The SpeeDx Resistance Plus® MG open-platform assay is CE marked for sale in Europe, TGA approved for sale in Australia and clinical trials are being finalised for submission to the U.S. FDA. Products in the SpeeDx portfolio focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease.
For more information on SpeeDx please see: https://plexpcr.com
Europe, Australia, New Zealand:
+61 2 9209 4170
Tel. + 1.408.400.4324
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Smiths Detection launches iCMORE algorithms for lithium batteries and dangerous goods for HI-SCAN 10080 XCT2.7.2020 12:00:00 EEST | Press release
Smiths Detection, a leading detection and security company, has launched iCMORE detection algorithms for lithium batteries and dangerous goods for use by its HI-SCAN 10080 XCT scanner, becoming its first explosive-detection system (EDS) to offer these options. The algorithms enhance the scanner’s detection capabilities by helping identify lithium batteries, flammable liquids and solids, and compressed and liquefied gasses, which can pose a risk should they ignite or explode. With iCMORE, Smiths Detection can now reliably and accurately detect potentially dangerous lithium batteries, alongside other dangerous goods, across both its conventional X-ray and its EDS technologies. The iCMORE lithium batteries and dangerous goods algorithms are complementary adaptions to existing screening technology. Although the screening of dangerous goods is not yet mandatory in hold-baggage and air-cargo screening, the increased level of safety for passengers, staff and assets is a key driver for the imp
EUSA Pharma Announces FDA Approval of Phase 3 Clinical Trial for Siltuximab in Hospitalized Patients With COVID-19 Associated Acute Respiratory Distress Syndrome2.7.2020 11:00:00 EEST | Press release
EUSA Pharma, a global biopharmaceutical company focused on oncology and rare disease, today announced that the U.S. Food & Drug Administration (FDA) has approved a randomized, double-blind, placebo-controlled Phase 3 clinical trial protocol to evaluate the safety and efficacy of intravenous siltuximab plus standard of care in hospitalized patients with COVID-19 associated Acute Respiratory Distress Syndrome (ARDS). Siltuximab is a monoclonal antibody that directly neutralizes interleukin (IL)-6, an inflammatory cytokine detected at elevated levels in multiple inflammatory conditions, including COVID-19. It specifically binds to IL-6, thereby inactivating IL-6 induced signalling. Lee Morley, Chief Executive Officer, EUSA Pharma, said: “Since the start of the pandemic, a growing body of evidence has been published highlighting that COVID-19 associated ARDS may exhibit features of systemic hyperinflammation, resulting from excessive cytokine production – the so-called ‘cytokine storm’ – w
Deenova Multiplies its Pharmacy Automation Market Presence into 7 European Countries2.7.2020 10:34:00 EEST | Press release
Deenova reported today its 2020 step-by-step but relentless continued geographic expansion into Austria, Belgium, France, Germany, Portugal, Spain, and Switzerland, with three new and seasoned business development staff totaling 66 years of healthcare industry experience. Christophe Jaffuel, Deenova’s International Business Development Director, stated: “I am extremely pleased to add Carlos Duran (formerly from Becton Dickinson-Carefusion-Rowa), Thierry Geraud (previously from Becton Dickinson-Carefusion-Pyxis) and Hilmi Sunay (recently from Omnicell-Health Robotics and Arxium-IHS Riva) to an already strong Deenova sales team. These 3 extremely talented and experienced individuals joined Deenova because of its unique technology and business approach to R.O.I., and total service solutions proven in the health care industry. I was equally impressed with Deenova’s demonstrated results when I joined the company 6 months ago, witnessing first-hand how Deenova simultaneously improves patient
Telstra Wholesale deploys ADVA technology in Australian-first Ethernet service2.7.2020 10:00:00 EEST | Press release
ADVA (FSE: ADV) today announced that Telstra Wholesale has deployed its FSP 150 packet edge device with LTE backup to deliver the new Ethernet Access – Mobile Backup service. Unique to the Australian market, the offering improves service availability and strengthens business continuity. With Layer 2 mobile backup capabilities, ADVA’s technology automatically switches traffic to Telstra Wholesale’s 4G mobile network if fiber connectivity fails. This helps to provide peace of mind for enterprise customers that no longer have the burden of configuring costly mobile backup and recovery systems. The new service is the latest stage in a long-standing partnership between ADVA and Telstra Wholesale, which has been key to advancing the reliability and resiliency of Ethernet services for Telstra Wholesale customers throughout Australia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200702005024/en/ ADVA’s packet edge technology is he
Urethral Stricture Treatment by Hybrid Cell Therapy, Granted Japanese Patent2.7.2020 09:00:00 EEST | Press release
Treating male urethral stricture with the patient’s own buccal mucosal cells, encapsulated in a polymer scaffold as carrier, has been granted a patent in Japan. A longer duration of relief to patients who had recurrence of the disease after earlier conventional treatments, has been reported by this method called “Bees-Haus” (Buccal epithelium Expanded and Encapsulated in Scaffold‐Hybrid Approach to Urethral Stricture; https://onlinelibrary.wiley.com/doi/full/10.1111/iju.13852). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200701006026/en/ Biomaterial research facility of JBM in Tokyo, where improvised scaffolds for regenerative medicine applications like Bees-haus, implants and medical devices are developed. (Photo: Business Wire) Male urethra, a tubular passage to let the urine out from urinary bladder, when affected with narrowing or stricture of the lumen, causes difficulty in voiding urine, urinary retention, and pain
Two in Five Fortune 500 Companies Choose Alibaba Cloud2.7.2020 09:00:00 EEST | Press release
Alibaba Cloud, the digital technology and intelligence backbone of Alibaba Group, said today it has supported 38 percent of the Fortune 500 companies over the past fiscal year. With this milestone, the cloud service provider plans to accelerate its globalization strategy, aiming to become the world’s leading digital intelligence backbone in three years. “We are extremely confident in the future of the global digital economy, especially with the digitalization of healthcare, business, education, leisure and other parts of our lives during the pandemic. As the largest cloud service provider in the Asia Pacific region, we will continue increasing investments in the next three years to strengthen our infrastructure, our solutions and our role in the wider technology ecosystem towards being the trusted partner of choice not just in Asia Pacific, but for the global digital economy by 2023,” said Jeff Zhang, president of Alibaba Cloud Intelligence, at the Alibaba Cloud Summit 2020 event. Cons
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom